Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...

Gender and ethnic disparities in breast cancer and cardiovascular disease-related mortality in United States from 1999-2019: A retrospective analysis. This is an ASCO Meeting Abstract from the 2025 ...

Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said. AbbVie and Genmab said ...

Integration of targeted therapies and immunotherapies offers new hope, enhancing survival rates and quality of life. Patients with mantle cell lymphoma experienced better survival rates when treated ...

(CNN) — An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial. The ...

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Among patients with relapsed/refractory diffuse large B-cell ...

Nivolumab plus AVD significantly improves PFS compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma, with a 91% vs 82% 3-year PFS rate. The PFS benefit of nivolumab plus ...

Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...

Stage 3 Hodgkin’s lymphoma either indicates lymphoma in the lymph nodes both above and below a person’s diaphragm or in the lymph nodes above the diaphragm and in the spleen. Doctors may also refer to ...